Pharma BD Deal Intelligence

Astellas Pharma Inc. / Maxygen, Inc. (Perseid Therapeutics stake)

2011 · Acquisition/Merger · $76M · Complete

Announcement Sentiment

Strongly positive

Astellas exercised its option to acquire Maxygen's stake in JV Perseid Therapeutics for $76M, taking full control of the protein-engineering platform and pipeline candidates. Below the typical $250M threshold but strategically notable for protein engineering consolidation.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Mar 17, 2011
Closed May 01, 2011
Deal value $76M
Deal type Acquisition/Merger
Therapeutic area Autoimmune / immunology preclinical assets
Indications Autoimmune / immunology preclinical assets
Key assets Perseid protein-engineering platform / Fc-fusion candidates
Mechanism MolecularBreeding directed evolution / protein engineering

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals